Page 2 - மையம் மருத்துவமனையாளர் யுனிவர்சிட்டேர் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

DBV Technologies S A : DBV Technologies to Participate in Upcoming AAAAI 2021 Congress

DBV Technologies S.A.: DBV Technologies to Participate in Upcoming AAAAI 2021 Congress DBV Technologies to Participate in Upcoming AAAAI 2021 Congress DBV Technologies (Euronext: DBV - ISIN: FR0010417345 - Nasdaq Stock Market: DBVT), a clinical-stage biopharmaceutical company, today announced upcoming participation at the virtual American Academy of Allergy, Asthma, and Immunology (AAAAI) Annual Scientific meeting, February 26 - March 1, 2021. Two scientific presentations have been accepted, including one clinical and one non-clinical poster. DBV will also host a virtual booth in the AAAAI virtual exhibit hall. The data to be presented will discuss a post-hoc analysis of the 12-month Phase 3 PEPITES clinical trial, showing that daily epicutaneous immunotherapy (EPIT) with DBV712 250 µg may reduce the severity of allergic reactions in peanut-allergic children aged 4 to 11 years. Additionally, DBV will present pre-clinical data suggesting that EPIT reduced mast-cell degranulation v

New yorkUnited statesFrance generalPierre louis hervAnne pollakAngela marcucciHugh sampsonPharis mohideenCentre hospitalier universitaireCompany adssCompany securitiesAmerican academy of allergyCompany annual report on formExchange commissionJaffe food allergy instituteIcahn school of medicine at mount sinai

Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)

Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm) Tonix Pharmaceuticals Holding Corp. Expands Proprietary Uses of Tonix’s Potentiated Oxytocin for Intranasal Administration Disorder Stunts Growth of Newborns and, Paradoxically, Can Cause Excessive Hunger During Childhood and Beyond CHATHAM, N.J., Feb. 11, 2021 (GLOBE NEWSWIRE) Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a clinical-stage biopharmaceutical company, today announced an agreement whereby Tonix has licensed technology using oxytocin-based therapeutics for the treatment of Prader-Willi syndrome and non-organic failure to thrive disease from Inserm. The licensing agreement has been negotiated and signed by Inserm Transfert, the private subsidiary of Inserm, on behalf of Inserm (the French National Institute of Health and Medical Research), Aix-Mar

Jessica morrisInserm transfertSeth ledermanOlipriya dasMarseille universitPeter vozzoCentre hospitalier universitaireTonix pharmaceuticalsService publicFoundation for prader willi researchResearch insermTonix pharmaceuticals holding corpDrug administration for orphanInserm transfert initiativeDrug administrationInserm the french national institute of health

Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)

Tonix Pharmaceuticals Licenses Technology for Treating Prader-Willi Syndrome, a Rare Genetic Eating Disorder, from the French National Institute of Health and Medical Research (Inserm)
benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.

Jessica morrisInserm transfertSeth ledermanOlipriya dasMarseille universitPeter vozzoCentre hospitalier universitaireTonix pharmaceuticalsService publicFoundation for prader willi researchResearch insermTonix pharmaceuticals holding corpDrug administration for orphanInserm transfert initiativeDrug administrationInserm the french national institute of health

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes

Anti-CD20 Therapy for Lymphoma Tied to Worse COVID-19 Outcomes
medscape.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medscape.com Daily Mail and Mail on Sunday newspapers.

New yorkUnited statesSylvain lamureMonica chenCentre hospitalier universitaireAmerican association for cancer researchReuters healthColumbia university vagelos college of physiciansAmerican associationCancer researchColumbia university vagelos collegeNew york presbyterian hospitalNew york cityபுதியது யார்க்ஒன்றுபட்டது மாநிலங்களில்மோனிகா சென்

Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting

Press release content from Business Wire. The AP news staff was not involved in its creation. Lantheus Holdings Announces Presentations Featuring its PSMA-Targeted Pipeline Product Candidates at the 2021 ASCO GU Annual Meeting February 4, 2021 GMT NORTH BILLERICA, Mass. (BUSINESS WIRE) Feb 4, 2021 Lantheus Holdings, Inc. (NASDAQ: LNTH) (the “Company”), the parent company of Lantheus Medical Imaging, Inc. and Progenics Pharmaceuticals, Inc., and a global leader in the development, manufacture and commercialization of innovative diagnostic and therapeutic agents and products, announced today three abstracts featuring its PSMA-targeted pipeline of product candidates have been selected for poster presentations at the upcoming 2021 American Society for Clinical Oncology Genitourinary (ASCO GU) Virtual Meeting, which will be held from February 11-13, 2021. Two of the abstracts relate to PyL™, the Company’s PET/CT imaging agent for prostate cancer, and the third abstract relate

New yorkUnited statesMemorial sloan kettering cancer centerNew jerseyNorth billericaJeremyc durackFrederic pouliotMark kinarneyOliver sartorBausch health companies incCentre hospitalier universitaireProgenics pharmaceuticals incTulane cancer centerLantheus medical imaging incCorporate communicationsLantheus holdings inc